|
Torisel has been approved for sale in Canada for the treatment of metastatic renal cell carcinoma. Torisel is an eligible benefit through some private insurance plans, some provincial and federal programs and is being reviewed for funding by other provincial/ territorial programs and federal plans. The Torisel Access Program (1-877-482-7457) will research and investigate reimbursement options for patients.
|